Shares of Supernus (SUPN) more than double in value, following word that it wins tentative FDA approval for its Trokendi XR treatment for epilepsy. Final authorization of the med depends on the firm settling a marketing exclusivity issue concerning a specific pediatric population. Additionally, the agency also rejected a Citizen’s Petition filed in 2011 by Upsher Smith Labs, that was linked to its New Drug Application for Trokendi XR.
Don’t Miss: Here Comes Amazon’s Fresh Tablet Attack.
UnitedHealth Group (NYSE:UNH) plans to create nearly 1,500 jobs in Texas, of which 800 will appear at the new solution center for its Connextions unit. The other positions will be located at a new fulfillment center and at operations centers in that state.
Roche (RHHBY.PK) says that it will shut down an research and development site in New Jersey, resulting in the loss of 1,000 jobs, and further unify its research activities at sites in Switzerland and Germany. However, Roche’s Genentech division will not be affected by the moves.
An acquisition of Dendreon (NASDAQ:DNDN) is probably not going to happen in the near-term, says Credit Suisse, which explained that it doesn’t seem that any majors are interested. Further, the analyst continues that Dendreon has been quietly reorganizing its business development team, and that its head, David Ghesquiere, might have exited the company more than a week ago.
Don’t Miss: Is Facebook’s Rally Merely a SHORT SQUEEZE?
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.